Fumagillin
(right click,save link as to download,it is a temp file,please download as soon as possible, you can also use CTRL+S to save the whole html page)
Basic Info
Common Name | Fumagillin(F05004) |
2D Structure | |
Description | Fumagillin is a mycotoxin found in the fungus Aspergillus fumigatus. It is an antimicrobial agent and amebicide that has been used in the treatment of microsporidiosis and other infections, especially in immunodeficient patients. It also has been investigated as a angiogenesis inhibitor in the treatment of cancer. Since fumagillin is often used to treat microsporidiosis in bees, it can be found as a contaminant in honey. (L1966, A3058) |
FRCD ID | F05004 |
CAS Number | 23110-15-8 |
PubChem CID | 6436022 |
Formula | C26H34O7 |
IUPAC Name | (2E,4E,6E,8E)-10-[[(3R,4S,5S,6R)-5-methoxy-4-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy]-10-oxodeca-2,4,6,8-tetraenoic acid |
InChI Key | NGGMYCMLYOUNGM-HTYDLQADSA-N |
InChI | InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20?,23-,24-,25?,26+/m1/s1 |
Canonical SMILES | CC(=CCC1C(O1)(C)C2C(C(CCC23CO3)OC(=O)C=CC=CC=CC=CC(=O)O)OC)C |
Isomeric SMILES | CC(=CCC1C(O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)OC)C |
Wikipedia | Fumagillin |
Synonyms | Fumagillin DCH fumagillin Amebacillin Fugilin Fugillin Fumidil Fumagillina [DCIT] Fumagilina [INN-Spanish] Fumagilline [INN-French] Fumagillinum [INN-Latin] |
Classifies | Fungal Toxin |
Update Date | Nov 13, 2018 17:07 |
Chemical Taxonomy
Kingdom | Organic compounds |
Superclass | Lipids and lipid-like molecules |
Class | Fatty Acyls |
Subclass | Fatty acids and conjugates |
Intermediate Tree Nodes | Not available |
Direct Parent | Medium-chain fatty acids |
Alternative Parents | |
Molecular Framework | Aliphatic heteropolycyclic compounds |
Substituents | Medium-chain fatty acid - Branched fatty acid - Epoxy fatty acid - Fatty acid ester - Heterocyclic fatty acid - Dicarboxylic acid or derivatives - Unsaturated fatty acid - Alpha,beta-unsaturated carboxylic ester - Enoate ester - Carboxylic acid ester - Organoheterocyclic compound - Oxacycle - Ether - Oxirane - Dialkyl ether - Carboxylic acid - Carboxylic acid derivative - Organooxygen compound - Hydrocarbon derivative - Organic oxide - Carbonyl group - Organic oxygen compound - Aliphatic heteropolycyclic compound |
Description | This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms. |
Properties
Property Name | Property Value |
---|---|
Molecular Weight | 458.551 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 11 |
Complexity | 879 |
Monoisotopic Mass | 458.23 |
Exact Mass | 458.23 |
XLogP | 4 |
Formal Charge | 0 |
Heavy Atom Count | 33 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Isotope Atom Count | 0 |
Covalently-Bonded Unit Count | 1 |
ADMET
Model | Result | Probability |
---|---|---|
Absorption | ||
Blood-Brain Barrier | BBB+ | 0.5248 |
Human Intestinal Absorption | HIA+ | 0.8342 |
Caco-2 Permeability | Caco2- | 0.5139 |
P-glycoprotein Substrate | Substrate | 0.6893 |
P-glycoprotein Inhibitor | Inhibitor | 0.6251 |
Inhibitor | 0.8337 | |
Renal Organic Cation Transporter | Non-inhibitor | 0.8420 |
Distribution | ||
Subcellular localization | Mitochondria | 0.8792 |
Metabolism | ||
CYP450 2C9 Substrate | Non-substrate | 0.8591 |
CYP450 2D6 Substrate | Non-substrate | 0.8809 |
CYP450 3A4 Substrate | Substrate | 0.6803 |
CYP450 1A2 Inhibitor | Non-inhibitor | 0.8653 |
CYP450 2C9 Inhibitor | Non-inhibitor | 0.8154 |
CYP450 2D6 Inhibitor | Non-inhibitor | 0.9412 |
CYP450 2C19 Inhibitor | Non-inhibitor | 0.8814 |
CYP450 3A4 Inhibitor | Non-inhibitor | 0.8680 |
CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.9559 |
Excretion | ||
Toxicity | ||
Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9768 |
Non-inhibitor | 0.8463 | |
AMES Toxicity | AMES toxic | 0.5360 |
Carcinogens | Non-carcinogens | 0.8927 |
Fish Toxicity | High FHMT | 0.7702 |
Tetrahymena Pyriformis Toxicity | High TPT | 0.9977 |
Honey Bee Toxicity | High HBT | 0.8319 |
Biodegradation | Not ready biodegradable | 0.8665 |
Acute Oral Toxicity | III | 0.5237 |
Carcinogenicity (Three-class) | Non-required | 0.5994 |
Model | Value | Unit |
---|---|---|
Absorption | ||
Aqueous solubility | -3.6957 | LogS |
Caco-2 Permeability | 0.8999 | LogPapp, cm/s |
Distribution | ||
Metabolism | ||
Excretion | ||
Toxicity | ||
Rat Acute Toxicity | 2.9093 | LD50, mol/kg |
Fish Toxicity | 0.6083 | pLC50, mg/L |
Tetrahymena Pyriformis Toxicity | 1.0949 | pIGC50, ug/L |
References
Title | Journal | Date | Pubmed ID |
---|---|---|---|
Toward a Cancer Drug of Fungal Origin. | Med Res Rev | 2015 Sep | 25850821 |
Review on Mycotoxin Issues in Ruminants: Occurrence in Forages, Effects of Mycotoxin Ingestion on Health Status and Animal Performance and Practical Strategies to Counteract Their Negative Effects. | Toxins (Basel) | 2015 Aug 12 | 26274974 |
Microsporidiosis: epidemiology, clinical data and therapy. | Gastroenterol Clin Biol | 2010 Sep | 20702053 |
Therapeutic strategies for human microsporidia infections. | Expert Rev Anti Infect Ther | 2005 Jun | 15954858 |
Microsporidiosis: an emerging and opportunistic infection in humans and animals. | Acta Trop | 2005 Apr | 15777637 |
Epidemiology of microsporidiosis: sources and modes of transmission. | Vet Parasitol | 2004 Dec 9 | 15567583 |
Toxicity and pharmacokinetics of the antibiotic fumagillin in yearling rainbow trout (Salmo gairdneri). | Toxicol Appl Pharmacol | 1989 May | 2718173 |
Mycoflora and mycotoxins of peanut (Arachis hypogaea L.) seeds in Egypt. III. Cellulose-decomposing and mycotoxin-producing fungi. | Mycopathologia | 1988 Oct | 3216881 |
Targets
- General Function:
- Poly(a) rna binding
- Specific Function:
- Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo.Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis.
- Gene Name:
- METAP2
- Uniprot ID:
- P50579
- Molecular Weight:
- 52891.145 Da
- Mechanism of Action:
- Fumagillin blocks blood vessel formation (angiogenesis) by inhibiting the enzyme methionine aminopeptidase 2. This prevents angiogenesis by arresting endothelial cells in the G1 phase of the cell cycle. Inhibition of angiogenesis can suppress tumor growth and metastasis. Methionine aminopeptidase 2 inhibition also blocks Wnt signaling, which plays a critical role in development, cell differentiation, and tumorigenesis.
References
- Hou L, Mori D, Takase Y, Meihua P, Kai K, Tokunaga O: Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis. Pathol Int. 2009 Jul;59(7):448-61. doi: 10.1111/j.1440-1827.2009.02393.x. [19563408 ]